254 related articles for article (PubMed ID: 23476047)
1. Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity.
Singh N; Tiem M; Watkins R; Cho YK; Wang Y; Olsen T; Uehara H; Mamalis C; Luo L; Oakey Z; Ambati BK
Blood; 2013 May; 121(20):4242-9. PubMed ID: 23476047
[TBL] [Abstract][Full Text] [Related]
2. Suppression of lymphangiogenesis by soluble vascular endothelial growth factor receptor-2 in a mouse lung cancer model.
Maehana S; Nakamura M; Ogawa F; Imai R; Murakami R; Kojima F; Majima M; Kitasato H
Biomed Pharmacother; 2016 Dec; 84():660-665. PubMed ID: 27697638
[TBL] [Abstract][Full Text] [Related]
3. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth.
Albuquerque RJ; Hayashi T; Cho WG; Kleinman ME; Dridi S; Takeda A; Baffi JZ; Yamada K; Kaneko H; Green MG; Chappell J; Wilting J; Weich HA; Yamagami S; Amano S; Mizuki N; Alexander JS; Peterson ML; Brekken RA; Hirashima M; Capoor S; Usui T; Ambati BK; Ambati J
Nat Med; 2009 Sep; 15(9):1023-30. PubMed ID: 19668192
[TBL] [Abstract][Full Text] [Related]
4. VEGF-trap aflibercept significantly improves long-term graft survival in high-risk corneal transplantation.
Dohlman TH; Omoto M; Hua J; Stevenson W; Lee SM; Chauhan SK; Dana R
Transplantation; 2015 Apr; 99(4):678-86. PubMed ID: 25606789
[TBL] [Abstract][Full Text] [Related]
5. Soluble vascular endothelial growth factor receptor-3 suppresses allosensitization and promotes corneal allograft survival.
Emami-Naeini P; Dohlman TH; Omoto M; Hattori T; Chen Y; Lee HS; Chauhan SK; Dana R
Graefes Arch Clin Exp Ophthalmol; 2014 Nov; 252(11):1755-62. PubMed ID: 25091513
[TBL] [Abstract][Full Text] [Related]
6. Combined blockade of VEGFR-3 and VLA-1 markedly promotes high-risk corneal transplant survival.
Zhang H; Grimaldo S; Yuen D; Chen L
Invest Ophthalmol Vis Sci; 2011 Aug; 52(9):6529-35. PubMed ID: 21715348
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib inhibits inflammatory corneal lymphangiogenesis.
Detry B; Blacher S; Erpicum C; Paupert J; Maertens L; Maillard C; Munaut C; Sounni NE; Lambert V; Foidart JM; Rakic JM; Cataldo D; Noël A
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3082-93. PubMed ID: 23580490
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.
Becker J; Pavlakovic H; Ludewig F; Wilting F; Weich HA; Albuquerque R; Ambati J; Wilting J
Clin Cancer Res; 2010 Mar; 16(5):1431-41. PubMed ID: 20179233
[TBL] [Abstract][Full Text] [Related]
9. Intracellular thiol redox status regulates lymphangiogenesis and dictates corneal limbal graft survival.
Fukumoto A; Maruyama K; Walsh T; Kajiya K; Hamuro J; D'Amore PA; Kinoshita S
Invest Ophthalmol Vis Sci; 2010 May; 51(5):2450-8. PubMed ID: 20042658
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.
Hos D; Bock F; Dietrich T; Onderka J; Kruse FE; Thierauch KH; Cursiefen C
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1836-42. PubMed ID: 18436817
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor receptor-3 is a novel target to improve net ultrafiltration in methylglyoxal-induced peritoneal injury.
Terabayashi T; Ito Y; Mizuno M; Suzuki Y; Kinashi H; Sakata F; Tomita T; Iguchi D; Tawada M; Nishio R; Maruyama S; Imai E; Matsuo S; Takei Y
Lab Invest; 2015 Sep; 95(9):1029-43. PubMed ID: 26121315
[TBL] [Abstract][Full Text] [Related]
12. Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity?
Goyal S; Chauhan SK; El Annan J; Nallasamy N; Zhang Q; Dana R
Arch Ophthalmol; 2010 Jul; 128(7):819-24. PubMed ID: 20625040
[TBL] [Abstract][Full Text] [Related]
13. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation.
Bachmann BO; Bock F; Wiegand SJ; Maruyama K; Dana MR; Kruse FE; Luetjen-Drecoll E; Cursiefen C
Arch Ophthalmol; 2008 Jan; 126(1):71-7. PubMed ID: 18195221
[TBL] [Abstract][Full Text] [Related]
14. Netrin-4 Mediates Corneal Hemangiogenesis but Not Lymphangiogenesis in the Mouse-Model of Suture-Induced Neovascularization.
Maier AB; Klein S; Kociok N; Riechardt AI; Gundlach E; Reichhart N; Strauß O; Joussen AM
Invest Ophthalmol Vis Sci; 2017 Mar; 58(3):1387-1396. PubMed ID: 28253401
[TBL] [Abstract][Full Text] [Related]
15. The newest member of the VEGF family.
Albuquerque RJ
Blood; 2013 May; 121(20):4015-6. PubMed ID: 23682028
[TBL] [Abstract][Full Text] [Related]
16. Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation.
Bock F; Onderka J; Dietrich T; Bachmann B; Pytowski B; Cursiefen C
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):115-9. PubMed ID: 17909835
[TBL] [Abstract][Full Text] [Related]
17. VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis.
Wuest TR; Carr DJ
J Exp Med; 2010 Jan; 207(1):101-15. PubMed ID: 20026662
[TBL] [Abstract][Full Text] [Related]
18. Expression of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in corneal lymphangiogenesis.
Mimura T; Amano S; Usui T; Kaji Y; Oshika T; Ishii Y
Exp Eye Res; 2001 Jan; 72(1):71-8. PubMed ID: 11133184
[TBL] [Abstract][Full Text] [Related]
19. Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors.
Pavlakovic H; Becker J; Albuquerque R; Wilting J; Ambati J
Ann N Y Acad Sci; 2010 Oct; 1207 Suppl 1(Suppl 1):E7-15. PubMed ID: 20961309
[TBL] [Abstract][Full Text] [Related]
20. Regulation of blood vessel versus lymphatic vessel growth in the cornea.
Chung ES; Saban DR; Chauhan SK; Dana R
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1613-8. PubMed ID: 19029028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
